PELLEGATA, NATALIA SIMONA
 Distribuzione geografica
Continente #
NA - Nord America 1.661
AS - Asia 1.230
EU - Europa 952
SA - Sud America 183
AF - Africa 105
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.135
Nazione #
US - Stati Uniti d'America 1.614
CN - Cina 444
SG - Singapore 296
HK - Hong Kong 206
IE - Irlanda 201
BR - Brasile 141
IT - Italia 139
RU - Federazione Russa 137
VN - Vietnam 113
DE - Germania 108
FR - Francia 90
FI - Finlandia 79
ZA - Sudafrica 78
UA - Ucraina 66
GB - Regno Unito 37
SE - Svezia 31
IN - India 30
BD - Bangladesh 24
CA - Canada 22
MX - Messico 17
JP - Giappone 15
IQ - Iraq 14
TR - Turchia 14
AR - Argentina 12
AT - Austria 11
ES - Italia 11
PK - Pakistan 10
PL - Polonia 10
CO - Colombia 9
ID - Indonesia 9
SA - Arabia Saudita 9
BE - Belgio 8
NL - Olanda 7
EG - Egitto 6
KE - Kenya 6
LT - Lituania 6
PH - Filippine 6
CL - Cile 5
EC - Ecuador 5
JO - Giordania 5
MA - Marocco 5
TH - Thailandia 4
UZ - Uzbekistan 4
KG - Kirghizistan 3
KH - Cambogia 3
MY - Malesia 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
ET - Etiopia 2
IL - Israele 2
IS - Islanda 2
KR - Corea 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
UY - Uruguay 2
VE - Venezuela 2
AM - Armenia 1
AU - Australia 1
CD - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
IR - Iran 1
LB - Libano 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
PF - Polinesia Francese 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
ZM - Zambia 1
Totale 4.135
Città #
San Jose 209
Hong Kong 201
Dublin 198
Chandler 186
Ashburn 174
Singapore 145
Dallas 134
Beijing 123
Boardman 75
Johannesburg 71
Jacksonville 61
Lauterbourg 57
Nanjing 57
Los Angeles 50
Helsinki 46
Ho Chi Minh City 39
Council Bluffs 36
Moscow 33
Redondo Beach 33
Lawrence 32
Princeton 32
Medford 30
Munich 28
Wilmington 28
Falkenstein 26
Hanoi 24
Milan 23
Santa Clara 22
New York 21
Hebei 19
Jiaxing 18
Nanchang 17
Shanghai 17
Buffalo 16
Chicago 16
São Paulo 16
The Dalles 15
Shenyang 14
Tokyo 14
Changsha 13
Monza 13
Chennai 12
Da Nang 12
Seattle 12
Brooklyn 11
Florence 11
Orem 11
Pavia 11
Tianjin 11
Toronto 10
Ann Arbor 9
Germering 9
Montreal 9
Brussels 8
Istanbul 8
Boston 7
Denver 7
Frankfurt am Main 7
Rio de Janeiro 7
Secaucus 7
Warsaw 7
Atlanta 6
Columbus 6
Guangzhou 6
Verona 6
Amman 5
Biên Hòa 5
Bologna 5
Cape Town 5
Haiphong 5
Kolkata 5
Nairobi 5
Padova 5
Phoenix 5
Rome 5
San Francisco 5
Vienna 5
Carbonara Scrivia 4
Caserta 4
Curitiba 4
Córdoba 4
Dhaka 4
Falls Church 4
Genoa 4
Hangzhou 4
Houston 4
Mosul 4
Newark 4
Tashkent 4
Alessandria 3
Amsterdam 3
Baghdad 3
Bishkek 3
Brasília 3
Cairo 3
Chiang Mai 3
Jakarta 3
Jaú 3
Manassas 3
Medellín 3
Totale 2.733
Nome #
Analysis and clinical implications of K-ras gene mutations and infection with human papillomavirus types 16 and 18 in primary adenocarcinoma of the uterine cervix 157
Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions 131
K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma 127
Primary retroperitoneal mucinous cystoadenocarcinomas: an immunohistochemical and molecular study 114
K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions 111
Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. 107
The novel SSTR3 full agonist ITF2984 shows antitumor properties against pancreatic neuroendocrine tumors (Pan-NETs) 106
A 5'-truncated c-myc gene variant not associated with a risk of cancer 102
Genetic events in sporadic colorectal adenomas; K-ras and p53 heterozygous mutations are not sufficient for malignant progression 95
Loss of heterozygosity and K-ras gene mutations in gastric cancer 94
Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients 94
Adiponectin affects the mechanical responses in strips from the mouse gastric fundus 91
Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects 89
Base transitions are the most frequent genetic changes at P53 in gastric cancer 89
Study on aneuploidy and p53 mutations in astrocytomas 88
Aip-mutated acromegaly resistant to first-generation somatostatin analogs: Long-term control with pasireotide lar in two patients 88
Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: A novel model of invasive medullary thyroid carcinoma 87
The significance of p53 mutations in human cancers 83
Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer 83
Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment 82
Animal models of MEN1 78
Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma 77
Mutation of the Cell Cycle Regulator p27kip1 Drives Pseudohypoxic Pheochromocytoma Development 77
Animal models of multiple endocrine neoplasia 71
Adipocyte-specific tribbles pseudokinase 1 regulates plasma adiponectin and plasma lipids in mice 71
Angpt2/Tie2 autostimulatory loop controls tumorigenesis 71
CDKN1B (p27) defects leading to pituitary tumors 69
The glucocorticoid receptor in brown adipocytes is dispensable for control of energy homeostasis 66
Obesity and cancer – extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases 65
Animal and Cell Culture Models of PPGLs – Achievements and Limitations 61
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 59
Editorial: Stem Cells in Endocrine Tumors 59
Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas 58
The norepinephrine transporter as a putative predictive biomarker for PI3K/mTOR inhibition in pheochromocytoma. 57
Tribbles Genes in Gastric Cancer: A Tumor-Suppressive Role for TRIB2 55
miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance 55
Multiple Endocrine Neoplasia Type 4 (MEN 4) 53
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures 53
Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics 52
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations 52
An AMP-activated protein kinase–stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice 50
Multiple Endocrine Neoplasia-Type 4 (MEN4) and Other MEN1-Like Syndromes 50
Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors 48
Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging 48
Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region 41
Systematic mapping of mitochondrial calcium uniporter channel (MCUC)-mediated calcium signaling networks 40
Multiple Endocrine Neoplasia Type 4 40
Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome 38
Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures 38
Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo 37
Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma 36
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses 36
Morphology, Biochemistry, and Pathophysiology of MENX-Related Pheochromocytoma Recapitulate the Clinical Features 35
Ovarian hyperstimulation from ectopic hypersecretion of follicle stimulating hormone 34
Primary Cell Culture Systems for Human Thyroid Studies 34
Inceptor correlates with markers of prostate cancer progression and modulates insulin/IGF1 signaling and cancer cell migration 34
Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models 32
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas 32
SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary 32
Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model 29
Simultaneous magnetic resonance imaging of pH, perfusion and renal filtration using hyperpolarized 13C-labelled Z-OMPD 29
Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas 29
Obesity in MENX Rats Is Accompanied by High Circulating Levels of Ghrelin and Improved Insulin Sensitivity 26
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study 25
Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome 22
Editorial: Obesity and metabolism in endocrine-related cancers 15
Mild chronic post-natal pain induces endocrine and metabolic alterations associated to enlargement in pituitary glands size in adult CD-1 male mice 13
Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant 8
Totale 4.208
Categoria #
all - tutte 20.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.572


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 0 3
2021/2022156 0 0 10 6 1 7 2 24 8 4 15 79
2022/2023550 44 47 4 31 63 59 2 31 246 3 12 8
2023/2024259 19 50 12 21 20 30 41 31 1 14 11 9
2024/2025879 20 64 9 20 8 83 74 64 212 34 83 208
2025/20261.932 153 121 209 172 240 119 343 131 153 158 71 62
Totale 4.208